NeOnc Technologies Holdings, Inc. Common Stock (NTHI)
🔔 Watch stock
NeOnc Technologies is one of only two hits in the sharpest signal combination of our own bankruptcy study: financial statements declared unreliable, an auditor who doubts the company can stay in business, and current liabilities larger than all current assets combined. We read the Form 10-Q for March 31, 2026 and the first audited annual report — plus every press release filed with the SEC since the listing. Read along before you mistake an announcement for a result.
Appears in These Scanners
This stock currently matches 12 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Quality & Screener
AI Rating
Uses AINeOnc hat im Oktober 2025 ein Patentportfolio mit KI-gestützten Wirkstoff-Suchwerkzeugen, magnetischem 3D-Biodruck und quantenmechanischer Modellierung gekauft (US-Patent 11.788.057 B2, 500.000 US-Dollar in Bar) und nutzt die KI-Plattform nach eigener Darstellung zur Vorhersage hirngängiger und ultraschall-empfindlicher Wirkstoffe in der präklinischen Forschung; Umsatz oder Produkt entsteht daraus nicht.
View the full file — quotes, sources, reviewed filings
„In 2025, we completed the acquisition of an intellectual property portfolio comprising artificial intelligence–driven drug discovery tools, rapid magnetic 3D bioprinting technology, and quantum molecular modeling capabilities, including U.S. Patent No. 11,788,057 B2. … The acquired technologies enable the rapid generation of patient-derived three-dimensional brain tumor organoids, AI-based prediction of CNS-penetrant and ultrasound-responsive compounds, and quantum-mechanical modeling of molecular behavior under focused ultrasound."
2025 haben wir den Erwerb eines Portfolios geistigen Eigentums abgeschlossen, das KI-gestützte Werkzeuge zur Wirkstoffsuche, schnellen magnetischen 3D-Biodruck und quantenmolekulare Modellierung umfasst, einschließlich des US-Patents Nr. 11.788.057 B2. … Die erworbenen Technologien ermöglichen die schnelle Erzeugung patientenabgeleiteter dreidimensionaler Hirntumor-Organoide, die KI-gestützte Vorhersage hirngängiger und ultraschall-empfindlicher Wirkstoffe sowie die quantenmechanische Modellierung des Molekülverhaltens unter fokussiertem Ultraschall.
„The Patent covers proprietary technologies combining 3D bioprinting, artificial intelligence, and quantum modeling that are designed to enable the creation of patient-derived three-dimensional brain tumor models for high-throughput preclinical drug screening."
Das Patent umfasst eigene Technologien, die 3D-Biodruck, künstliche Intelligenz und Quantenmodellierung verbinden und die Erzeugung patientenabgeleiteter dreidimensionaler Hirntumor-Modelle für die präklinische Wirkstoffprüfung im Hochdurchsatz ermöglichen sollen.
„NTHI has acquired and operationalized an AI-driven computational drug modeling platform designed to support the rational development of sonosensitizers, including the Company’s lead assets, NEO100 and NEO212. This proprietary platform enables predictive modeling of blood-brain barrier (BBB) permeability, reactive oxygen species (ROS) generation, and drug-tumor interactions across heterogeneous CNS tumor environments."
NTHI hat eine KI-gestützte rechnergestützte Wirkstoff-Modellierungsplattform erworben und in Betrieb genommen, die die zielgerichtete Entwicklung von Sonosensibilisatoren unterstützen soll, darunter die Leitkandidaten NEO100 und NEO212. Diese eigene Plattform ermöglicht die vorhersagende Modellierung der Durchgängigkeit der Blut-Hirn-Schranke, der Bildung reaktiver Sauerstoffspezies und der Wechselwirkungen zwischen Wirkstoff und Tumor in unterschiedlichen Tumorumgebungen des Zentralnervensystems.
Filings Reviewed: 10-Q 2026-05-15 · 10-K 2026-03-31 · 10-K/A 2026-05-05 · 10-Q 2025-11-14 · 10-Q 2025-08-18 · 424B4 2025-03-25
Rated on July 26, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.09 | – | 0 | – | -11,265.00 | -1 | -1 |
| 2025: Q1 | -1.47 | – | 0 | -7.00 | -95,005.00 | -6 | -6 |
| 2025: Q2 | -0.22 | – | 0 | -100.00 | – | -5 | -5 |
| 2025: Q3 | -0.33 | – | 0 | – | – | -6 | -6 |
| 2025: Q4 | -0.60 | – | 0 | -100.00 | – | -4 | -4 |
| 2026: Q1 | -0.34 | – | 0 | -100.00 | – | -7 | -7 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Assessment: Opportunities & Risks
Cash stood at $138,601 on March 31, 2026 against $6,991,773 of net cash used in operating activities during the quarter. On four of six quarterly reporting dates since the end of 2024 the balance was around $100,000. On May 18, 2026 the company itself cited a runway "into September 2026."
Current assets of $2,095,163 against current liabilities of $16,287,621 (coverage ratio 0.13, below 1 on all six reporting dates). Those liabilities include $7,208,666 of withheld but unremitted payroll taxes and $4,304,110 from a 2024 litigation settlement. Shareholders' equity was minus $13,231,165.
The first quarterly report as a public company was declared unreliable (August 18 and 20, 2025); the required statement about discussions with the auditors had to be added after an SEC letter. Internal control as of December 31, 2025 and disclosure controls as of March 31, 2026 were not effective by the company's own assessment. The auditor resigned six days after the listing.
According to its own prospectus, the selling programme of April 10, 2026 can turn 24,911,482 shares into up to 38,877,962. Add 2,093,305 warrants with down-round protection, a convertible preferred converting at a 20 percent discount to the five-day low, and a proposal for the August 14, 2026 annual meeting to expand the incentive plan by 20 percent each year.
Of $58,280,435 of 2025 operating expenses, $35,555,059 was share-based compensation and $11,787,806 advisory fees — including $11,328,565 to the chief executive's own firm, triggered by the listing itself. Research and development cost $3,638,257. The first $7.0 million from the new selling programme is earmarked for the outstanding payroll taxes.
The mechanism is documented: NEO100 and its metabolite were detectable in the tumour tissue of a treated patient. Orphan drug designation since 2011, fast track since 2016. No serviceable financial debt remains, and not a single insider sale was reported in twelve months — the chief executive bought in eleven tranches into falling prices.
NeOnc Technologies is working on a real medical problem and has a mechanism demonstrated in a human being: the compound is delivered as a nasal mist and was detectable inside tumour tissue. At the same time the company trips all three warning signals of our bankruptcy study — a quarterly report declared unreliable, a going-concern paragraph in the audit report, and current liabilities above current assets. Cash was $138,601 on March 31, 2026 against $16,287,621 of current liabilities, including $7.2 million of withheld payroll taxes that were never remitted. Of the 2025 net loss of $62.1 million, $35.6 million was share-based compensation and $11.8 million advisory fees, but only $3.6 million research. The likelier danger for shareholders is not insolvency but dilution. Not investment advice.
- NTHI reached our research list as one of exactly two hits in our in-house scanner "Bankruptcy study: the sharpest triple combination" (as of July 26, 2026). The combination of the three signals has triggered 98 times since 2005, just under nine times a year; 53 percent of those stocks lost at least 30 percent within three months against 11 percent in a control group matched on price, trading volume and distance from the 52-week high. Four out of five of these companies survive the year — the model is a smoke detector, not a demolition order. Scanner lists are recalculated daily.
- How the window works: signals count for twelve months. The oldest of the three is the Item 4.02 filing of August 20, 2025. Without a new signal, NeOnc drops out of this combination on August 20, 2026 even if nothing on the balance sheet changes.
- Ratio trap: price-to-earnings and price-to-sales are meaningless here (no profit, $39,990 of annual revenue). The Altman Z-score also produces nothing but an artefact, because total assets of $3,330,161 are smaller than a single quarter's deficit. The reliable measures are the simple ones: cash $138,601, coverage ratio 0.13, shareholders' equity minus $13,231,165 (all March 31, 2026).
- Currency note: the latest quarterly report (Form 10-Q) is dated May 15, 2026 and has been fully analysed. Every filing after it has been reviewed — current reports dated May 18, June 12, June 18, June 23, July 2 and July 15, 2026, a shelf registration dated June 15, 2026, a prospectus supplement and the proxy statement dated June 23, 2026, and insider filings through July 13, 2026. No financial statements exist yet for the quarter ended June 30, 2026; the deadline runs to mid-August 2026. There is no Form 15, no Form 25 and no listing deficiency notice.
- Easily confused: the market debut on March 25/26, 2025 was a direct listing, not an initial public offering — there was no offering price and no proceeds. That distinction is not cosmetic here: a $4.3 million dispute with former partner Orient EuroPharma turns on it, because the settlement tied payment to an "initial public offering." The withdrawn 2024 IPO attempt would have covered 6,000,000 shares at $11.25 to $13.75.
About the Company
NeOnc Technologies Holdings, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, konzentriert sich auf die Entwicklung von Behandlungen für intrakranielle Malignome.
| Employees | 5 |
|---|---|
| Headquarters | Calabasas, CA |
| Website | neonc.com |
| IPO Date | 26. Mar 2025 |
| Next Earnings | 17. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Amir Farrokh Heshmatpour | President, CEO, Executive Chairman & Secretary | 1967 |
| Thomas C. Chen M.D., Ph.D. | Founder, Chief Medical Officer, Chief Scientific Officer & Vice Chairman | 1965 |
| Keithly A. Garnett | Chief Financial Officer | 1975 |
| Josh Neman-Ebrahim Ph.D. | Chief Clinical Officer | 1978 |
| David Choi Jr. | Chief Accounting Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.